RGS4 polymorphism and response to electroconvulsive therapy in major depressive disorder.
We studied the association between RGS4 (rs951436) polymorphism and treatment response in electroconvulsive therapy (ECT) as well as risk of treatment-resistant depression. The study sample consisted of 119 patients with major depressive disorder (MDD) and 384 healthy control subjects. RGS4 polymorphism was not associated with treatment response in ECT or risk of MDD. According to the present data, the impact of RGS4 genotype is not decisive in major depressive disorder. The results provide preliminary data on the impact of RGS4 polymorphism in treatment response in ECT.
Huuhka
Kaija
K
University of Tampere, Medical School, Department of Psychiatry, Tampere University Hospital, Tampere, Finland. kaija.huuhka@pshp.fi
Kampman
Olli
O
Anttila
Sami
S
Huuhka
Martti
M
Rontu
Riikka
R
Mattila
Kari M
KM
Hurme
Mikko
M
Lehtimäki
Terho
T
Leinonen
Esa
E
D020121:5' Untranslated Regions / Q000235:genetics; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000928:Antidepressive Agents / Q000627:therapeutic use; D003865:Major Depressive Disorder / Q000235:genetics* / Q000628:therapy*; D004351:Drug Resistance; D004565:Electroconvulsive Therapy; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D011569:Psychiatric Status Rating Scales; D020710:RGS Proteins / Q000235:genetics*; D055815:Young Adult
D020121:5' Untranslated Regions; D000928:Antidepressive Agents; D020710:RGS Proteins; C098799:RGS4 protein